Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of AGAMREE, or vamorolone. If approved, AGAMREE would be the first and only therapy approved by Health Canada with an indication for the treatment of Duchenne muscular dystrophy, or DMD. Health Canada has granted AGAMREE a priority review and marketing authorization could be granted before the end of 2025. News of the AGAMREE priority review was welcomed by national patient organizations. The Canadian Neuromuscular Disease registry estimates that there are more than 800 boys and young men living with DMD in Canada and coping with its debilitating symptoms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Biotech Alert: Searches spiking for these stocks today
- Elastic, Monster, Caesars, Catalyst, Corbus: Stock Shake-Up!
- Catalyst Pharmaceuticals price target raised to $32 from $28 at Baird
- Catalyst Pharmaceuticals price target raised to $40 from $33 at Stephens
- Catalyst Pharmaceuticals Reports Record 2024 Financial Results